ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$270.56
−0.21%Year over year
Reported trailing growth
- Revenue
- +114.8%
- EBITDA
- +151.8%
- EBIT
- +143.2%
- EPS
- +365.9%
- Free cash flow
- +297.2%
- Operating cash flow
- +313.0%
Forward estimates
Based on analyst estimates
- Revenue
- +62.7%
- EBITDA
- +922.7%
- EPS
- -48.4%
Three-year CAGR
- Revenue
- +138.2%
- EBITDA
- +62.1%
- EBIT
- +53.0%
- Net income
- +42.1%
- EPS
- +44.6%
- Free cash flow
- +114.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026